The DOI matches its Crossref record; 91 of the 95 references it cites were found in a registry or an index; 93 of the 201 sources its claims cite were checked for support.
Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions
Open accessAbstract
This critical review identifies pharmacokinetic, dose, and temporal conflicts that hinder the translation of theranostic nanoplatforms for AD.
Overview
CoChat Summary
## TL;DR
This is a critical review arguing that current Alzheimer’s disease theranostic nanoplatforms are constrained by three fundamental conflicts: pharmacokinetic, dose, and temporal mismatches. The authors conclude that the “one particle for everything” model has not translated clinically and recommend alternative strategies such as preclinical “hit-and-clear” intervention, separate diagnostic/therapeutic particles, and theranostic monitoring.
## Key findings
- The review identified three core conceptual conflicts in AD theranostics:
- Pharmacokinetic conflict: diagnostics need rapid accumulation and clearance, while therapy needs prolonged retention.
- Dose conflict: diagnostic and therapeutic doses often differ by orders of magnitude; the paper states 13–400-fold or greater disparities, and in one example diagnostic and therapeutic doses for SPIONs were reported as 5860 mg/kg vs 25–100 mg/kg.
- Temporal conflict: imaging is typically short-term, but AD therapy is chronic/lifelong, making repeat diagnostics difficult because particles can generate persistent background signals.
- The authors say only 23 studies were selected for their representative analysis of existing nanotheranostic systems for AD.
- Brain delivery is reported as very limited in the few studies with quantitative data, with accumulation of only 1.94% ID/g for a nanosweeper system and 1.12–1.57% ID/g for mesoporous NPs with dual targeting.
- The paper highlights a methodological trap: much of the field focuses on mature Aβ fibrils, even though the authors argue soluble Aβ oligomers are the more toxic species and should be prioritized.
## Methods
- This is a critical review, not a systematic review; the authors explicitly say they chose a conceptual analysis rather than an exhaustive catalog.
- They performed a literature search in PubMed, Scopus, and Web of Science covering January 2015 to December 2024, using AD/nanomedicine/theranostic keywords.
- Inclusion criteria: original peer-reviewed research on AD nanoplatforms with dual diagnostic and therapeutic functionality in in vitro or in vivo models; exclusion criteria included diagnosis-only, therapy-only, reviews, conference abstracts, editorials, book chapters, and non-AD neurodegenerative studies.
## Limitations
- The authors state the sample was selective rather than exhaustive, because the goal was conceptual analysis rather than complete coverage.
- They note that heterogeneous experimental models, dosing protocols, efficacy measures, and units prevent correct quantitative comparison across studies.
- They also acknowledge that negative results are often not publicly available, which may distort the apparent success of approaches.
- Evident from the text: many conclusions rest on a small set of representative studies, and several cited studies are preclinical only, often in models such as transgenic mice or *C. elegans*, limiting direct clinical inference.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
65 Valid · 7 Not valid · 54 Not checked · 103 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Liu and co-authors [67] provide quantitative dissociation constants for oligomers (68.3 nM) and fibrils (112.5 nM) of Aβ”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 2. Molecular Targets of Theranostics > 2.4. Methodological Trap: Fibrils vs. Oligomers
What the sources say
- Disputedcites [67] Liu, 2022, Dual-Targeted Magnetic Mesoporous Silica Nanoparticles Reduce Brain Amyloid-β Burden via Depolymerization and Intestinal Metabolism, Theranostics sourceExperimental — accuracy not yet measured
The Characterization of HA-MMSN-1F12 section reports an oligomer-binding Kd of 1.27 ± 0.34 nM for HA-MMSN-1F12, not 68.3 nM. It gives no fibril Kd of 112.5 nM; a search for those values and for fibril dissociation constants found no matching passage in our copy. (LLM, conf=0.87)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51],”
- Also stated in: § 2.2. Hyperphosphorylated Tau-Protein · plain
“Hyperphosphorylated tau accumulation correlates more robustly with cognitive decline and neuronal loss than Aβ [49,51]”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 2. Molecular Targets of Theranostics > 2.2. Hyperphosphorylated Tau-Protein
What the sources say
- Not checked — no full text of the sourcecites [49] Mullane, 2018, Alzheimer’s Disease (AD) Therapeutics—2: Beyond Amyloid—Re-Defining AD and Its Causality to Discover Effective Therapeutics, Biochem. Pharmacol. source
- Partly supportedcites [51] Nisbet, 2015, Tau Aggregation and Its Interplay with Amyloid-β, Acta Neuropathol. sourceExperimental — accuracy not yet measured
The section “Synergistic roles of Aβ and tau in AD” (page unavailable) links increased tau aggregation to dendritic spine loss and accelerated cognitive impairment, and reports improved memory in mice when tau is reduced without changing Aβ levels. The copy does not establish that hyperphosphorylated tau accumulation correlates more robustly than Aβ with cognitive decline or neuronal loss. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2.2. Hyperphosphorylated Tau-Protein · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Current AD therapy is limited to symptomatic treatment [13].”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 1. Introduction
What the sources say
- Supportedcites [13] Cummings, 2018, Lessons Learned from Alzheimer Disease: Clinical Trials with Negative Outcomes, Clin. Transl. Sci. source
Lesson 4 describes symptomatic therapies as providing short-term improvement, while Lesson 10 says that no working model has guided successful disease-modifying therapy development. Together with the Summary’s description of successful AD drug development as an unmet need, these passages support the claim in the paper’s 2018 context. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The most toxic forms of Aβ are not mature fibrils, but soluble oligomers [65].”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 2. Molecular Targets of Theranostics > 2.4. Methodological Trap: Fibrils vs. Oligomers
What the sources say
- Supportedcites [65] Francisco, 2024, Recent Advances in Fluorescent Theranostics for Alzheimer’s Disease: A Comprehensive Survey on Design, Synthesis, and Properties, ACS Omega source
The Amyloid-β Targeting Theranostics section explicitly says that cumulative clinical and nonclinical evidence supports soluble Aβ oligomers being more neurotoxic than insoluble Aβ fibrils in plaques. This directly supports the citing sentence’s comparison with mature fibrils. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“pathological changes in the brain begin to accumulate many years before the appearance of clinical symptoms [12]”
§ Theranostic Nanoplatforms for Alzheimer’s Disease: A Critical Analysis of Conceptual Contradictions > 1. Introduction
What the sources say
- Partly supportedcites [12] Rasmussen, 2019, Alzheimer’s Disease—Why We Need Early Diagnosis, Degener. Neurol. Neuromuscul. Dis. sourceExperimental — accuracy not yet measured
The ‘Improving Alzheimer’s Disease Diagnosis Rates’ section says that people with preclinical Alzheimer’s disease can have signs of pathology despite having no cognitive symptoms. It does not establish that those pathological changes begin accumulating many years before clinical symptoms. Its reference to up to eight years concerns detection of mild cognitive impairment before dementia symptoms, not pathology before any clinical symptoms; page numbers are unavailable in our copy. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
118 more claims · 34 with their cited sources checked
Create a free account to see all 229 claims and to verify the 4 references still open.
- It may state two separate claims as one. 93
- Probably not a substantial claim. 19
Citations
Cites
The Amyloid Hypothesis of Alzheimer’s Disease: Progress and Problems on the Road to Therapeutics
Hardy, J., & Selkoe, D. J. (2002) · Science · doi:10.1126/science.1072994 · Cited by 13,864
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
Alzheimer Disease: An Update on Pathobiology and Treatment Strategies
Long, J. M., & Holtzman, D. M. (2019) · Cell · doi:10.1016/j.cell.2019.09.001 · Cited by 3,204 · cited 1×
“Furthermore, all existing methods of AD treatment are used lifelong, since the disease has a chronic progressive course with a preclinical phase starting 10–20 years before the onset of symptoms, and an inevitable fatal outcome within 5–12 years after their onset [90].”
Knopman, D. S., Amieva, H., Petersen, R. C., Chételat, G., Holtzman, D. M., Hyman, B. T., Nixon, R. A., & Jones, D. T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00269-y · Cited by 2,606
Gold nanoparticles in biomedical applications: recent advances and perspectives
Dykman, L., & Khlebtsov, N. (2012) · Chem. Soc. Rev. · doi:10.1039/c1cs15166e · Cited by 1,961
Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease
Salloway, S., Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1304839 · Cited by 1,960 · cited 1×
“For example, bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47], while crenezumab also failed to meet primary endpoints [13].”
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668 · cited 1×
“For example, bapineuzumab and solanezumab showed no cognitive improvement in Phase 3 trials [46,47], while crenezumab also failed to meet primary endpoints [13].”
Liposomes: Structure, composition, types, and clinical applications
Nsairat, H., Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09394 · Cited by 1,561 · cited 1×
“Each class possesses unique properties: lipid particles (liposomes, exosomes) offer biocompatibility [23–25]; polymeric particles (Poly(lactic-co-glycolic acid) (PLGA), dendrimers) provide biodegradability and functionalization [19,26]; superparamagnetic iron oxide Nps (SPIONs) enable MRI contrast…”
Zhang, J., Zhang, Y., Wang, J., Xia, Y., Zhang, J., & Chen, L. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01911-3 · Cited by 1,138
Kobayashi, H., Watanabe, R., & Choyke, P. L. (2014) · Theranostics · doi:10.7150/thno.7193 · Cited by 996 · cited 1×
“The key success factor is the presence of solid tumors with disrupted vascular architecture, which provides a pronounced enhanced permeability and retention (EPR) effect [32,34].”
Cited by
Targeted nanomedicine strategies for Alzheimer’s disease therapy
Ardah, M. T., Yaseen, B. M., Malathi, H., Ray, S., Thyagarajan, R., Shankhyan, A., Eshmetov, R., Ataullaev, Z., & Mishra, M. K. (2026) · Discover Nano · doi:10.1186/s11671-026-04763-8 · Cited by 3
“In late-stage dementia, amyloid-only strategies are less likely to restore function unless paired with interventions that address Tau pathology, neuroinflammation, synaptic loss, mitochondrial injury, or neurovascular dysfunction [162, 163].”
Metadata
- Authors
- Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V.
- Affiliations
- Federal Medical Research Centre for Psychiatry and Narcology (RU)
- Corresponding author
- Zorkina, Yana
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2026-04-16
- Volume
- 27
- Issue
- 8
- Pages
- 3560
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC13115951
- OpenAlex
- W7154576422
- Cited by
- 1
- References
- 95
- Citations by year
- 2026: 1
- FWCI
- 1.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (publishedVersion, cc-by)
- Funders
- Russian Science Foundation (25-75-10063)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
- Keywords
- Alzheimer's disease, theranostics, nanoplatforms, clinical translation, pharmacokinetics, temporal conflict, amyloid-beta oligomers, stimuli-responsive nanoparticles, brain drug delivery
- MeSH terms
- Theranostic Nanomedicine, Alzheimer Disease, Animals, Humans, Amyloid beta-Peptides, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions. https://app.cochat.ai/papers/10.3390/ijms27083560
- The paper
- Zorkina, Y., Abramova, O., Zubkov, E., Gurina, O., & Ushakova, V. (2026). Theranostic Nanoplatforms for Alzheimer's Disease: A Critical Analysis of Conceptual Contradictions. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27083560
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.